Tracers / [125I]PARPi-01
[125I]PARPi-01
- Radionuclide
- I-125 t½ 85666 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- PARP inhibitor (Olaparib derivative)
- Target / mechanism
- PARP1 (Poly ADP-ribose Polymerase 1) PMID 36104637
- Clinical application
- PARP targeted Auger emitter therapy for triple-negative breast cancer PMID 36104637
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC+SPE | 78 ± 12% | >95% | Tributyl stannylated derivative of Olaparib | 36104637 2022 EJNMMI Res Radiolabelling was conducted as previously described [17] — The resulting overall radiochemical yield was 78 ± 12% with purities of > 95%. |
Need this precursor?We can point you to suppliers for [125I]PARPi-01, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36104637. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36104637: 'Tributyl stannylated derivative of Olaparib'. Stage set/updated at stage 23 from PMID 36104637: 'In this study, a theranostic approach was investigated in a TNBC xenografted mouse model by radiolabelling a close derivative of a PARPi Olaparib (termed PARPi-01) with the Auger emitters 123/125I.'.